CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million , representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarter First and only cell therapy clinically shown to significantly extend overall survival versus standard

CARVYKTI ®   (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 million MHRA and Health Canada approved CARVYKTI ® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma CARVYKTI ®   demonstrates positive overall

SOMERSET, N.J. , July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024 . For the six-months ended June 30, 2024 , Legend Biotech

CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis SOMERSET, N.J. , July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global leader in cell therapy, announced today

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI ® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma Legend and Johnson & Johnson enter into

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $159 million and $500 million for the fourth quarter and full year 2023, respectively CHMP recommended CARVYKTI ® label expansion in earlier lines of treatment for adult patients with relapsed and